Lead Product(s) : Human Fibrinogen,Thrombin
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Corza
Deal Size : $427.0 million
Deal Type : Divestment
Takeda to Divest TachoSil® to Corza Health for €350 Million
Details : Under the terms of the agreement, upon close, Corza Health will acquire the assets and licenses that support the development and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria.
Product Name : TachoSil
Product Type : Large molecule
Upfront Cash : 427.0 million
September 16, 2020
Lead Product(s) : Human Fibrinogen,Thrombin
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Corza
Deal Size : $427.0 million
Deal Type : Divestment
Lead Product(s) : Human fibrinogen,Thrombin
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Johnson & Johnson
Deal Size : $400.0 million
Deal Type : Termination
Johnson & Johnson Abandons Deal for Takeda's Tachosil Surgical Patch
Details : In late March, EU antitrust regulators had expressed concern about the deal and opened a full investigation into it.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
April 10, 2020
Lead Product(s) : Human fibrinogen,Thrombin
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Johnson & Johnson
Deal Size : $400.0 million
Deal Type : Termination
Reset All
